President and CEO Bob Proulx today addressed investors at the Switzer Small and Microcap Investor Day in Sydney Australia. He discussed recent milestones, including FDA
Appendix 4E and 2019 Full Year Results Key Developments Achieved for MagSense® Imaging Technology Imagion Biosystems has released its Appendix 4E and Preliminary Results for
Imagion Biosystems Limited (ASX: IBX) (the Company), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide an update
Form 605, “Notice of ceasing to be a substantial holder”, has been released to the ASX. Read Form 605.
Imagion Biosystems has today released its Appendix 4C Quarterly Cash Flow Report and update on Company activities for the quarter ending 31 December 2019. Read
Imagion Biosystems announces the appointment of Oliver Steinbach PhD to the position of Vice President Clinical and Regulatory Affairs. Read the announcement.
“Appendix 3B New issue announcement” has been released by Imagion Biosystems. Read Appendix 3B New Issue Announcement.
Imagion Biosystems has announced the following Response to Price Query with the ASX. Read the Response to Price Query.
The following response to “Appendix 3Y — Change of Director’s Interest Notice Query” has been announced. Read the response.
Imagion Biosystems has released “Notice Pursuant to Section 708A(5)(e) of the Corporations Act.” Read the notice.